M
Masashi Fujii
Researcher at Nihon University
Publications - 148
Citations - 5217
Masashi Fujii is an academic researcher from Nihon University. The author has contributed to research in topics: Cancer & Colorectal cancer. The author has an hindex of 24, co-authored 128 publications receiving 4495 citations.
Papers
More filters
Journal ArticleDOI
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
Shinichi Sakuramoto,M. Sasako,Toshiharu Yamaguchi,Taira Kinoshita,Masashi Fujii,Atsushi Nashimoto,Hiroshi Furukawa,Toshifusa Nakajima,Yasuo Ohashi,Hiroshi Imamura,Masayuki Higashino,Yoshitaka Yamamura,Akira Kurita,Kuniyoshi Arai +13 more
TL;DR: S-1 is an effective adjuvant treatment for East Asian patients who have undergone a D2 dissection for locally advanced gastric cancer and has a higher rate of overall survival than the surgery-only group.
Journal ArticleDOI
Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer
Mitsuru Sasako,Shinichi Sakuramoto,Hitoshi Katai,Taira Kinoshita,Hiroshi Furukawa,Toshiharu Yamaguchi,Atsushi Nashimoto,Masashi Fujii,Toshifusa Nakajima,Yasuo Ohashi +9 more
TL;DR: On the basis of 5-year follow-up data, postoperative adjuvant therapy with S-1 was confirmed to improve overall survival and relapse-free survival in patients with stage II or III gastric cancer who had undergone D2 gastrectomy.
Journal ArticleDOI
Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial
Kazuhiro Yoshida,Yasuhiro Kodera,Mitsugu Kochi,Wataru Ichikawa,Yoshihiro Kakeji,Takeshi Sano,Narutoshi Nagao,Masazumi Takahashi,Akinori Takagane,Takuya Watanabe,Masahide Kaji,Hiroshi Okitsu,Takashi Nomura,Takanori Matsui,Takaki Yoshikawa,Jin Matsuyama,Makoto Yamada,Seiji Ito,Masahiro Takeuchi,Masashi Fujii +19 more
TL;DR: Addition of docetaxel to S-1 is effective with few safety concerns in patients with stage III gastric cancer, and the present findings may also be applicable in countries in which perioperative adjuvant chemotherapy or chemoradiation is not standard.
Journal ArticleDOI
Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer.
Mitsugu Kochi,Masashi Fujii,Noriaki Kanamori,Teruo Kaiga,Tetsuya Kawakami,Kazuo Aizaki,Mitsuko Kasahara,Fumiro Mochizuki,Yuichi Kasakura,Motoo Yamagata +9 more
TL;DR: Serum CEA level is an independent prognostic factor in patients with primary gastric cancer and is a useful indicator of curability in patients who undergo gastrectomy.
Journal ArticleDOI
State of the art in the treatment of gastric cancer: from the 71st Japanese Gastric Cancer Congress.
TL;DR: In the panel discussions at the 71st Gastric Cancer Congress of Japan, 18 representative institutions and hospitals in Japan reported their latest results for the surgical treatment of Gastric cancer, indicating the state of the art in the treatment of gastric cancer.